Press Releases

Jun. 10 OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery AQ
May. 20 Absci to Participate in Upcoming Investor Conferences GL
May. 07 Absci : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) PU
May. 07 Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results GL
May. 07 Absci : Corporate Presentation, May 2026 PU
May. 04 Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GL
Apr. 23 Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026 GL
Apr. 08 Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference GL
Mar. 24 Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results GL
Mar. 24 Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic GL
Mar. 24 Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic AQ
Mar. 06 Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GL
Mar. 03 Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer GL
Feb. 24 Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 GL
Feb. 17 Absci to Participate in Upcoming Investor Conferences GL
Dec. 16 Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference GL
Dec. 16 Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference AQ
Dec. 12 AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave AQ
Dec. 11 Absci : ABS-201 KOL Seminar Presentation PU
Dec. 11 Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization GL
Dec. 10 Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research GL
Dec. 04 Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia GL
Nov. 12 Absci : Corporate Presentation, Fall 2025 PU
Nov. 12 Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results GL
25-10-29 Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025 GL
No results match your criteria
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!